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Abstract
Aim: To assess the role of human bocavirus 1 (HBoV1) as a causative agent of non-
severe community-acquired pneumonia (CAP) in children.
Methods: Patients aged 2-59 months with non-severe CAP (respiratory complaints
and radiographic pulmonary infiltrate/consolidation) attending aUniversity Hospital in
Salvador, Brazil were enrolled in a prospective cohort. From 820 recruited children in a
clinical trial (ClinicalTrials.gov NCT01200706), nasopharyngeal aspirate (NPA), and
acute and convalescent serum samples were obtained from 759 (92.6%) patients.
NPAs were tested for 16 respiratory viruses by PCR. Acute HBoV1 infection was
confirmed by measuring specific IgM and IgG responses in paired serum samples.
Results: Respiratory viruses were detected in 693 (91.3%; 95%CI: 89.1-93.2) CAP
cases by PCR. HBoV1-DNA was detected in 159 (20.9%; 95%CI: 18.2-24.0) cases. Of
these 159PCRpositive cases, acuteHBoV1 infectionwas confirmed serologically in 38
cases (23.9%; 95%CI: 17.8-31.0). Overall, acute HBoV1 infection was confirmed in
5.0% (38/759) of non-severe CAP patients. HBoV1 was detected in 151 cases with at
least one other virus making 31.7% of all multiple virus (n = 477) detections. Among all
759 cases, 216 had one respiratory virus detected, and sole HBoV1 was detected in
only 8 (3.7%). Acute HBoV1 infection was serologically diagnosed in 34 (22.5%)
HBoV1-DNA-positive cases with another virus, compared to 4 (50.0%) cases with sole
virus detection (p = 0.09).
The abstract of this manuscript was orally presented during the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases Research Masterclass, held in Madrid,
Spain, on May 27, 2017.
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Conclusion: HBoV1 was detected by PCR in one fifth of the children with non-severe
CAP and acute HBoV1 infection was serologically confirmed in one quarter of these
cases.
K E YWORD S
acute respiratory infection, children, lower respiratory tract infection, respiratory virus, viral
infection
1 | INTRODUCTION
Community-acquired pneumonia (CAP) remains a major cause of
hospitalization and death among children under 5 years of age
worldwide.1 Due to its significance in public health and social economy
development,2 effective measures are needed to control this
condition.3
The real role of respiratory viruses in the pathogenesis of CAP
remains debatable. This concerns especially human bocavirus 1
(HBoV1) which is mostly detected with other respiratory viruses and
is often detected in asymptomatic subjects.4 HBoV1 has, since its
discovery in 2005,5 been found in 10-20% of nasopharyngeal
aspirate samples (NPA) of hospitalized children with lower respira-
tory illness.6–8 However, HBoV1-DNA has been shown to persist for
weeks or even months after an acute infection, detectable as low
viral loads in the NPAs, questioning the clinical value of PCR-based
diagnosis.9 In 2008, it was shown that by measurement of HBoV1-
specific IgM and IgG antibodies, it was possible to diagnose acute
HBoV1 infection in children hospitalized with acute severe
respiratory diseases.9 In the current study, we used specific serology
to assess the frequency of acute HBoV1 infections in children with
both non-severe CAP and with HBoV1-DNA detected by PCR in the
nasopharyngeal mucus.
2 | MATERIALS AND METHODS
2.1 | Study design
A prospective study was conducted at the Federal University of Bahia
Hospital in Salvador, Northeast Brazil (clinical trial on the use of
amoxicillin, ClinicalTrials.gov Identifier NCT01200706) from Novem-
ber 2006 to April 2011. Cases were community-dwelling children aged
between 2 and 59 months with non-severe CAP, who came to the
Pediatric Emergency Department. CAP was diagnosed by a pediatri-
cian on duty. Diagnosis was based on respiratory complaints (cough or
difficulty breathing) associated with lower respiratory pathologic
findings plus presence of pulmonary infiltrate or consolidation on the
chest radiograph (CXR) (frontal and lateral views) taken on admission
and read by the pediatrician on duty. Non-severe CAP cases were
identified when CAP cases did not present any of the following
findings: lower chest indrawing, inability to drink, seizure, somnolence,
central cyanosis, grunting in a calm child, and nasal flaring (World
Health Organization criteria for severity of CAP, 2000).10 The
exclusion criteria were: chronic debilitating diseases (anatomic
abnormalities of the respiratory tract, cancer, chronic pulmonary
illness besides asthma, immunological defects, progressing neurologi-
cal disorders, psychomotor retardation, heart disease with clinical
repercussion, hemoglobinopathy, liver or kidney disease, severe
malnutrition), other concurrent infection, HIV-infected mother,
hospitalization during the previous 7 days, amoxicillin or other
antibiotics use during the last 48 h, allergy to amoxicillin, or history
of aspiration. The primary results of this trial have been published.11
The assessment of respiratory virus detection was a secondary
objective in the clinical trial.
On enrolment, after written informed consent had been obtained
from parents/legal guardians, every patient was evaluated by trained
medical students under the supervision of a senior pediatrician, all from
the research team. A complete physical examination was performed.
Data on demographics, clinical history, and physical examination were
recorded in pre-defined forms with the following variables: age, sex,
disease duration, complaints (cough, fever, difficulty breathing,
wheezing, vomiting), axillary temperature, respiratory rate (RR),
weight, findings on physical examination (chest retraction, reduced
pulmonary expansion, rhonchi, wheezing, crackles). A follow-up visit
was scheduled to occur 2-4 weeks after recruitment. Fever was
defined as axillary temperature >37.4°C12 and tachypnea as RR ≥ 50
breaths/min in children aged 2-11 months or RR ≥40 breaths/min in
children from 12 to 59 months of age.13 Nutritional evaluation was
performed using the software Anthro, version 1.02 (Centre for Disease
Control and Prevention and WHO) and malnutrition and severe
malnutrition were defined as Z-score for weight-for-age index under
−2.00 or −3.00, respectively, using the National Centre for Health
Statistics standard.14
2.2 | Sampling and microbiological analyses
NPA and acute serum samples were collected from each patient upon
admission and convalescent serum samples were collected on the
follow-up visit. The NPA was aspirated through a nostril with a
disposable mucus extractor inserted into the nasopharynx. Each
sample was immediately placed in an identified empty tube and frozen
at −80°C at the Federal University of Bahia Hospital Laboratory
pending shipment to the research laboratories. After data collection
was finished, the NPA samples were sent to the University of Turku,
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Department of Clinical Virology, Turku, Finland, whereas the paired
serum samples were sent to the University of Helsinki, Department of
Virology, Helsinki, Finland, by airplane maintained at −80°C. After
thawing and nucleic acid extraction, a multiplex real-time PCR test kit
(Anyplex [TM] II RV16, Seegene, Seoul, South Korea) was used to
detect: human adenovirus (HAdV), influenza A (Flu A) and B (Flu B)
viruses, parainfluenza virus types 1-4 (PIV 1, PIV 2, PIV 3, PIV 4),
rhinovirus (RV), respiratory syncytial viruses A (RSV A) and B (RSV B),
HBoV1, coronaviruses 229E (HCoV 229E), NL63 (HCoV NL63), and
OC43 (HCoV OC43), metapneumovirus (hMPV), and enteroviruses
(EV) in NPA. The Anyplex (TM) II RV16 detection kit is a multiplex real-
time PCR assay based on tagging oligonucleotide cleavage extension.
In addition, an in-house PCR test was used to detect EV and RV in NPA
samples, as previously described.15 Due to the known long persistence
of HBoV1-DNA in the airways, specific IgM and IgG were measured in
159 paired serum samples of HBoV1-DNA-positive patients. The
diagnostic criteria of an acute primary HBoV1 infection was the
presence of one of the following markers: presence of IgM, a fourfold
or greater increase or conversion of IgG in paired sera. The HBoV IgG
and the my-capture IgM enzyme immunoassays (EIAs) have been
described elsewhere.16,17 Recombinant virus-like particles of VP3
were used as antigen in the two EIAs and cross-reacting antibodies for
HBoV2 and 3were blocked. The cutoff absorbance values for antibody
presence (mean + 4 SDs) were 0.095 for our competition IgG and
0.131 for IgM.17 Borderline results in all EIAs were considered
indeterminate.
2.3 | Preventive measures for PCR contamination
The PCR methodology is highly vulnerable to possible false positive
results due to contamination of reagents and specimens with PCR
amplicons. The analyses were performed in an accredited clinical virus
diagnostic laboratory. In the present work, rigorous measures were
taken throughout thewhole study to avoid amplicon as well as sample-
to-sample contamination.
2.4 | Statistical analyses
Sample size was estimated as 73 cases with HBoV1 detected in NPA,
considering an expected frequency of acute serologically diagnosed
HBoV1 infection equal to 5%, total width of confidence interval (CI)
of 10% and 95% CI. We performed a bivariate analysis: the
frequency of each clinical characteristic of children with or without
acute HBoV1 infection was compared by using chi-square or Fisher's
exact test as appropriate; continuous variables were presented as
median (interquartile range [IQR]) and were assessed by using Mann-
Whitney U test due to non-parametrical distribution. The tests were
two-tailed with significance at <0.05. As the frequency of missing
information was very low, we chose to handle the absent data by
excluding these cases. All laboratory procedures were performed by
trained personnel blinded to clinical data. All analyses were
performed using the Statistical Package for the Social Sciences
(SPSS), Version 9.0.
2.5 | Ethics approval
This study was conducted in accordance with the Declaration of
Helsinki and national and institutional standards. It was approved by
the Ethics Committee of the Federal University of Bahia (Approval
reference number 24/2006).
3 | RESULTS
A total of 820 children were enrolled in the clinical trial. Of these, 759
(92.6%) children had NPA and acute and convalescent serum samples
collected and were included in this study. The median (IQR) interval
between collection of acute and convalescent samples was 19 (16-22)
days. Table 1 presents the baseline characteristics of the 759 studied
cases. All NPA samples were tested for 16 viruses. Viruses were
detected in 693 samples (91.3%; 95% CI: 89.1-93.2) and HBoV1 was
found in 159 (20.9%; 95% CI: 18.2-24.0) cases. Of 159 PCR-positive
cases, acute or recent HBoV1 infection was confirmed serologically in
38 cases (23.9 %; 95%CI: 17.8-31.0). Overall, acute or recent HBoV1
infection was confirmed in 5.0% (38/759).
Out of 693 cases with virus detection, 477 (68.8%: 95%CI:
65.3-72.2) had multiple viruses detected, among which HBoV1 was
found in 151 (31.7%). Conversely, out of 216 cases with sole virus
detection, HBoV1 was detected in 8 (3.7%) (P < 0.001). Acute HBoV1
infection was serologically diagnosed in 34 (22.5%) of the HBoV1 cases
with at least oneother virus, compared to4 (50.0%) caseswith sole virus
detection (P = 0.09). Among those 34 caseswith acuteHBoV1 infection
and multiple virus detection, 11 (32.4%) cases had 1 virus detected, 12
(35.3%) cases had 2 viruses detected, 6 (17.6%) cases had 3 viruses
detected, 3 (8.8%) caseshad4virusesdetected, and2 (5.9%) caseshad5
viruses detected alongside HBoV1, being up to 6 respiratory viruses
concomitantly found. Figure 1 demonstrates the frequency of each
respiratory virus found among these cases. Rhinovirus was the most
frequently found virus being detected in 50% of these cases whereas
neither Flu A nor PIV 2 were detected. Table 1 also shows the
comparison between cases with or without acute HBoV1 infection. No
significant differences were found when children with acute HBoV1
sole infection were compared with children with acute HBoV1 and
multiple virus detections (Table 2). Figure 2 presents the monthly
distributionof caseswith acuteHBoV1 infection diagnosedby serology,
of caseswithHBoV1detected inNPA, andof the recruitedCAPcases in
each month of the study period.
4 | DISCUSSION
In this study, we found that 21% of children with non-severe CAP had
HBoV1-DNA in their nasopharynx but only one quarter of them
showed serologic evidence of acute or recent HBoV1 infection. Three
quarters of PCR-positive HBoV1 detections in children with CAPwere
not associated with the current infection being most probably due to
prolonged shedding after a previous HBoV1 infection. In agreement
with many earlier studies we detected HBoV1 in the majority of cases
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together with other respiratory viruses. Importantly, one fifth of the
children with multiple viral detections had acute HBoV1 infection
showing that HBoV1 in coinfections is not always just an innocent
bystander.
With the use of HBoV1 serodiagnosis it has been clearly shown
that by 6 years of age all children have been infected with HBoV1.18 In
the original serodiagnosis study of Kantola et al, 59% of 49 HBoV1-
DNA-positive children with acute wheezing exhibited IgM antibodies
and/or an increase in IgG antibody levels.9 Don et al19 found that 12%
of 101 children with CAP had serological evidence of acute HBoV1
infection. Seven of 12 patients were hospitalized. Some members of
this research team have previously studied serologically HBoV1
infection in 273 children hospitalized due to CAP20; with strict criteria
8% of these CAP patients had evidence of acute HBoV1 infection. Our
observations and those of others strongly suggest that HBoV1 is a
causative agent of childhood CAP. Furthermore, the observations
suggest that in half of HBoV1 acute infection CAP cases, the illness is
clinically non-severe thus not necessitating hospitalization.
TABLE 1 Baseline characteristics of children with non-severe community-acquired pneumonia and comparison between cases with or without
acute human bocavirus 1 infection
All cases Acute HBoV1 infectiond
Characteristics (n = 759) n (%)a Yes (n = 38)a No (n = 721)a
Demographics
Age (median [IQR] months) 25.5 (13.4-40.1) 21.7 (13.3-26.9) 25.8 (14.0-40.5)
Male gender 398 (52.4) 16 (42.1) 382 (53.0)
History
Disease duration(median [IQR] days) 5 (4-8) 6.5 (4.0-8.0) 5.0 (4.0-8.0)
Cough 739/757b (97.6) 37 (97.4) 702/719c (97.6)
Fever 702/758b (92.6) 38 (100.0) 664/720c (92.2)
Difficulty breathing 472/757b (62.4) 27 (71.1) 445/719c (61.9)
Vomiting 337/758b (44.5) 16 (42.1) 321/720c (44.6)
Physical examination
Rhonchi 493/758b (65.0) 26 (68.4) 467/720c (64.9)
Crackles 343/758b (45.3) 20 (52.6) 323/720c (44.9)
Tachypnea 340/758b (44.9) 16 (42.1) 324/720c (45.0)
Wheezing 225/758b (29.7) 12 (31.6) 213/720c (29.6)
Reduced pulmonary expansion 64/757b (8.5) 3 (7.9) 61/719c (8.5)
Malnutrition 29/758b (3.8) 1 (2.6) 28/720c (3.9)
Chest retraction 28/758b (3.7) 1 (2.6) 28/720c (3.8)
IQR, interquartile range.
aExpressed as absolute number and percentage if not otherwise specified.
bThe denominator was not 759 because there was missing information.
cThe denominator was not 721 because there was missing information.
dNo statistically significant difference was found when cases with or without acute HBoV1 infection were compared.
FIGURE 1 Frequency (%) of respiratory viruses detected among 34 children with acute human bocavirus 1 infection alongside multiple
other viruses detected
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The widely used multiplex PCR tests have greatly increased our
understanding of the role of respiratory viruses in pneumonia. In many
studies in children with CAP, respiratory viruses have been detected in
50-70% of the cases.4 However, many viruses including HBoV1 have
been detected at similar or higher rates in asymptomatic controls
which has questioned whether these viruses are causative agents of
CAP.21–23 This concept is debatable, because respiratory viruses may
also cause asymptomatic infections which explains the detection of
viruses in asymptomatic subjects.15,24,25 Recently, serology has made
an important contribution to this question. In the study of Zhang et al,
in children with CAP, serology and RT-PCRmostly agreed but serology
for RSV, hMPV, PIV 1-3, and HAdV increased the diagnostic yields,
ranging from 12% to 49%.26 Interestingly, after an acute infection
HBoV1 is the only respiratory virus with prolonged viral shedding
lasting longer than 1-3 weeks,27 which is why serology markedly
decreases the yield of HBoV1 diagnoses compared with PCR in the
nasopharyngeal mucus. It is of note that HBoV1-asymptomatic acute
infections have not been reported. In one study, none of 28
asymptomatic HBoV1-DNA-positive children had spliced HBoV1
mRNA in their nasopharyngeal mucus suggesting that the viruses
detected were not replicating.28
The clinical role of multiple respiratory virus detection in the
pathogenesis of childhood CAP is not fully understood. Recently
published reports have concluded that there is no association between
multiple respiratory virus detection and disease severity.29,30 In our
study, multiple viruses were detected in approximately 70% of the
cases with virus-positive non-severe CAP. Our study suggests that
HBoV1 might have a pathogenic role in children with CAP, also with
multiple virus detection.
Cases were randomly found among all months of the year in this
study (Figure 2). Among Lebanese children hospitalized either with
bronchiolitis or with CAP, HBoV1-DNA was found in airways samples
in all seasons, except spring.31 This may be explained by the difference
in the weather conditions during the year in each of these countries:
while Lebanon has mild weather allowing the occurrence of significant
temperature and climate changes, Brazil is a tropical country having
steady climate conditions throughout the year.
Our study has certain limitations. The study was a single center
study limiting wider generalization of the observations. Due to
economical restrictions, HBoV1 serology was studied only from
HBoV1-DNA-positive patients. It is probable that also studying
HBoV1-DNA-negative CAP children would have increased our
diagnostic yield. In the study on acute wheezing 13% of children
TABLE 2 Comparison between cases with acute HBoV1 sole
infection and cases with acute human bocavirus 1 infection and
multiple viruses detection
Acute HBoV1 infection
Characteristics
Sole infection
(n = 4)a
Multiple
viruses detection
(n = 34)a P
Demographics
Age (median
[IQR] months)
29.0
(15.3-44.8)
21.1 (13.3-26.7) 0.2
Male gender 1 (25.0) 15 (44.1) 0.6
History
Disease duration
(median [IQR]
days)
5.5 (4.0-13.0) 6.5 (3.8-8.0) 0.9
Cough 4 (100.0) 33 (97.1) 1.0
Fever 4 (100.0) 34 (100.0) -
Difficulty breathing 2 (50.0) 25 (73.5) 0.6
Vomiting 3 (75.0) 13 (38.2) 0.3
Physical examination
Rhonchi 3 (75.0) 23 (67.6) 1.0
Crackles 3 (75.0) 17 (50.0) 0.6
Tachypnea 2 (50.0) 14 (41.2) 1.0
Wheezing 1 (25.0) 11 (32.4) 1.0
Reduced pulmonary
expansion
0 (0.0) 3 (8.8) 1.0
Malnutrition 0 (0.0) 1 (2.9) 1.0
Chest retraction 0 (0.0) 1 (2.9) 1.0
IQR, interquartile range.
aExpressed as absolute number and percentage if not otherwise specified.
FIGURE 2 Monthly distribution (n) of cases with acute human bocavirus 1 infection diagnosed by serology, of cases with human bocavirus
1 detected in nasopharyngeal aspirate samples, and of the recruited community-acquired pneumonia cases in each month of the study period
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who tested negative for HBoV1-DNA in the nasopharynx showed
serologic evidence of acute HBoV1 infection.9 Furthermore, we did
not study HBoV1 copy numbers nor HBoV1 DNA in the serum.
However, it has been previously shown in a Finnish study that 38%
of the children with low-load PCR positivity have acute infection
diagnosed by serology whereas 96% of the high-load positive PCR
have the same serological diagnosis.16 Therefore, serology should be
enough to show reliably the actual acute infections. Moreover, it was
very recently published that when compared with serology, DNA
PCR had high clinical sensitivity (100%) but, because of viral
persistence, low specificity (76%).32 An additional limitation is that
no virus-bacterial co-infections were analyzed. The strength of our
study includes a long recruitment period lasting almost four and half
years, reducing the risk of bias regarding viral seasonality, and a high
number of CAP patients. In addition, the serologic studies were
carried out in a well-established laboratory of HBoV1 virology. It has
been recognized that serology is the most accurate method to
diagnose acute HBoV1 infection, even when it was compared to
detection of HBoV1 messenger RNA which implies viral
replication.32
In conclusion, our observations provide further support for the
causal role of HBoV1 in the pathogenesis of childhood CAP, both as a
sole agent or with other respiratory viruses.
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